UNIVERSITY OF UTAH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1850-02-28

Employees: 10K

Market Cap: -

Website: http://www.utah.edu

Clinical Trials

Validation of Frontal EEG to Formal Polysomnography in the ICU

Not Applicable

Terminated

Conditions: Sleep
Sleep Deprivation

Interventions: Device: 2-lead limited electroencephalography recording

First Posted Date: 2017-10-26

Last Posted Date: 2021-06-08

Lead Sponsor: University of Utah

Target Recruit Count: 44

Registration Number: NCT03322371

Locations: 🇺🇸
University of Utah, Salt Lake City, Utah, United States

Sleep/Wake Protocol Implementation to Improve Sleep Quality in the ICU

Completed

Conditions: Delirium
Sleep Deprivation

Interventions: Behavioral: Sleep/Wake Protocol

First Posted Date: 2017-10-18

Last Posted Date: 2023-04-25

Lead Sponsor: University of Utah

Target Recruit Count: 685

Registration Number: NCT03313115

Locations: 🇺🇸
University of Utah, Salt Lake City, Utah, United States

Precision-exercise-prescription for Lung Cancer Patients Undergoing Surgery: The PEP Study

Phase 3

Completed

Conditions: Non Small Cell Lung Cancer
Secondary Lung Cancer

Interventions: Behavioral: Personalized Exercise Program

First Posted Date: 2017-10-11

Last Posted Date: 2023-06-07

Lead Sponsor: University of Utah

Target Recruit Count: 200

Registration Number: NCT03306992

Locations: 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States

Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to Bone

Phase 2

Completed

Conditions: Prostate Cancer Metastatic to Bone

Interventions: Drug: Radium Ra 223 Dichloride
Radiation: Radiation

First Posted Date: 2017-10-09

Last Posted Date: 2024-02-12

Lead Sponsor: University of Utah

Target Recruit Count: 20

Registration Number: NCT03304418

Locations: 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States

Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis

Phase 2

Terminated

Conditions: IDH1 Gene Mutation
Plasma Cell Myeloma
Secondary Myelofibrosis
ASXL1 Gene Mutation
EZH2 Gene Mutation
Primary Myelofibrosis
Anemia
IDH2 Gene Mutation
Recurrent Plasma Cell Myeloma
Thrombocytopenia

Interventions: Drug: Busulfan
Drug: Cyclophosphamide
Drug: Fludarabine
Procedure: Hematopoietic Cell Transplantation
Other: Laboratory Biomarker Analysis

First Posted Date: 2017-10-06

Last Posted Date: 2022-05-05

Lead Sponsor: University of Utah

Target Recruit Count: 6

Registration Number: NCT03303950

Locations: 🇺🇸
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States

Behavioral Interventions for Chronic Pain and Opioid-Related Problems

Not Applicable

Completed

Conditions: Chronic Pain

Interventions: Behavioral: Mindfulness-Oriented Recovery Enhancement
Behavioral: Supportive Counseling

First Posted Date: 2017-10-02

Last Posted Date: 2021-12-10

Lead Sponsor: University of Utah

Target Recruit Count: 95

Registration Number: NCT03298269

Locations: 🇺🇸
College of Social Work, Salt Lake City, Utah, United States

Study for the Treatment of Ocular Chronic Graft-Versus-Host Disease (GVHD) With Amniotic Fluid Eye Drops (AFED)

Phase 1

Completed

Conditions: Ocular Graft Versus Host Disease

Interventions: Other: Saline Solution
Biological: Amniotic Fluid Eye Drops (AFED)

First Posted Date: 2017-10-02

Last Posted Date: 2023-07-07

Lead Sponsor: University of Utah

Target Recruit Count: 15

Registration Number: NCT03298815

Locations: 🇺🇸
University of Utah Huntsman Cancer Institute, Salt Lake City, Utah, United States

Merestinib on Bone Metastases in Subjects With Breast Cancer

Phase 1

Terminated

Conditions: Bone Metastases
Breast Cancer

Interventions: Drug: Merestinib

First Posted Date: 2017-09-25

Last Posted Date: 2021-01-08

Lead Sponsor: University of Utah

Target Recruit Count: 2

Registration Number: NCT03292536

Locations: 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States

[18F]Fluciclovine and [18F]FLT PET/CT Assessment of Primary High-Grade Brain Tumors

Phase 1

Terminated

Conditions: Brain Tumor

Interventions: Drug: [18F]FLT
Drug: [18F]Fluciclovine

First Posted Date: 2017-09-08

Last Posted Date: 2024-12-27

Lead Sponsor: University of Utah

Target Recruit Count: 10

Registration Number: NCT03276676

Locations: 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States

Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma

Phase 2

Terminated

Conditions: Melanoma

Interventions: Drug: Nivolumab
Drug: HF10

First Posted Date: 2017-08-23

Last Posted Date: 2022-06-13

Lead Sponsor: University of Utah

Target Recruit Count: 7

Registration Number: NCT03259425

Locations: 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy